Saroglitazar sulfoxide D4

Saroglitazar sulfoxide D4 is a synthetic compound used in the treatment of dyslipidemia and diabetes. It is a derivative of Saroglitazar, which is an orally active drug that acts as a dual PPARα/γ agonist. Saroglitazar sulfoxide D4 is a deuterated form of Saroglitazar, which enhances its stability and efficacy. The chemical formula of Saroglitazar sulfoxide D4 is C40H28D4F2N2O6S2, and its molecular weight is 764.87 g/mol. It is a yellow crystalline powder that is soluble in dimethyl sulfoxide (DMSO), ethanol, and methanol. The compound shows high bioavailability and is rapidly absorbed after oral administration. Saroglitazar sulfoxide D4 works by activating the peroxisome proliferator-activated receptors (PPARs) in the liver and muscles. This results in improved lipid and glucose metabolism, which helps in reducing the levels of triglycerides, LDL cholesterol, and blood glucose. The compound has been shown to be effective in clinical trials and has a good safety profile. In conclusion, Saroglitazar sulfoxide D4 is a promising drug for the treatment of dyslipidemia and diabetes. Its deuterated form enhances its stability and efficacy, making it a suitable candidate for further development.